Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
NeoTX Therapeutics Ltd.
National Institutes of Health Clinical Center (CC)
7 Hills Pharma, LLC
Incyte Corporation
Incyte Corporation
University Hospital, Angers
Telix Pharmaceuticals (Innovations) Pty Limited
Sotio Biotech Inc.
Molecular Templates, Inc.
Western Sydney Local Health District
Jules Bordet Institute
Institut Bergonié
Xencor, Inc.
Incyte Corporation
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Shenzhen BinDeBio Ltd.
Masonic Cancer Center, University of Minnesota
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)